ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interstitial lung disease"

  • Abstract Number: 038 • 2023 Pediatric Rheumatology Symposium

    HLA-DRB1*15 Alleles in Systemic Juvenile Idiopathic Arthritis with Lung Disease and Macrophage Activation Syndrome in Italy

    Claudia Bracaglia1, Manuela Pardeo1, Maria Troiano2, Giuseppe Testa2, Ivan Caiello1, Arianna De Matteis3, Matteo Trevisan1, Franco Locatelli4, Marco Andreani2 and Fabrizio De Benedetti1, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, 2Laboratory of Transplant Immunogenetics, Department of Haematology/Oncology, Cell and Gene, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Lazio, Italy, 3Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Roma, Italy, 4Ospedale Pediatrico Bambino Gesù, Department of Hematology/Oncology, Cell and Gene Therapy, Roma, Italy

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is characterized by unique clinical features and it is considered as a polygenic autoinflammatory disease. Macrophage activation syndrome (MAS)…
  • Abstract Number: 095 • 2023 Pediatric Rheumatology Symposium

    Systemic Juvenile Idiopathic Arthritis Associated Lung Disease in Europe

    Claudia Bracaglia1, Francesca Minoia2, Christoph Kessel3, Sebastiaan Vastert4, Manuela Pardeo1, Alessia Arduini1, Sarka Fingerhutova5, Irina Nikishina6, Ozge Basaran7, Nural Kiper8, Mikhail Kostik9, Mia Glerup10, Roberta Caorsi11, AnnaCarin Horne12, Giovanni Filocamo2, Helmut Wittkowski3, Marija Jelusic13, Jordi Anton14, Samira Khaldi-Plassart15, Alexandre Belot15, Gerd Horneff16, Seraina Palmer Sarrott17, Elvira Cannizzaro Schneider18, Lampros Fotis19, Pavla Dolezalova5, Angelo Ravelli20, Seza Ozen7 and Fabrizio De Benedetti1, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, 2Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico, Milano, Italy, 3Department of Pediatric Rheumatology & Immunology, WWU Medical Center (UKM), Muenster, Germany, 4Wilhelmina Children’s Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, The Netherlands, Utrecht, Netherlands, 5Centre for Paediatric Rheumatology and Autoinflammatory Diseases, Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, 6V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 7Department of Pediatrics, Division of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, 8Department of Pediatrics, Division of Pediatric Pulmonology, Hacettepe University, Ankara, Turkey, 9Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, 10Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, 11Department of Pediatrics and Rheumatology, IRRCS Istituto G. Gaslini, Genova, Italy, 12Department of pediatric rheumathology Karolinska University Hospital and Department of pediatrics, Karolinska Institute, Stockholm, Sweden, 13Department of Paediatrics, University of Zagreb School of Medicine, University Hospital Centre, Zagreb, Croatia, 14Pediatric Rheumatology, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain, 15Pediatric Nephrology, Rheumatology, Dermatology Unit, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France, 16Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 17Paediatric Rheumatology University Children’s Hospital Zurich, Zurich, Zurich, Switzerland, 18Paediatric Rheumatology University Children’s Hospital Zurich, Zurich, Switzerland, 19Pediatric Rheumatology Division, 3rd Department of Pediatrics, National and Kapodistrian University of Athens,‘’ATTIKON’’ General University Hospital, Athens, Greece, 20IRRCS Istituto Giannina Gaslini and Università degli Studi di Genova, Genova, Italy

    Background/Purpose: Chronic parenchymal lung disease (LD) is a new emerging severe life-threatening complication of sJIA. The number of sJIA patients with LD is apparently increasing…
  • Abstract Number: 098 • 2023 Pediatric Rheumatology Symposium

    Characterization of Pulmonary Nodules in Juvenile-onset Systemic Sclerosis: A Single Center Case-Series

    Jonathan Li1, Franziska Rosser1, Sameh Tadros1 and Kathryn Torok2, 1UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Given the high prevalence of intestinal lung disease (ILD) in systemic sclerosis (SSc) and the low sensitivity of pulmonary function testing for diagnosing ILD,…
  • Abstract Number: 0123 • ACR Convergence 2022

    Increase of Serum Endothelin-1 Levels in Patients with Interstitial Lung Disease Associated with Autoimmune Diseases

    Sara Remuzgo-Martinez1, Belén Atienza-Mateo1, Veronica Pulito-Cueto1, Fernanda Genre1, Víctor M. Mora-Cuesta1, David Iturbe-Fernández1, Virgi Portilla1, María Sebastián Mora-Gil1, J Gonzalo Ocejo-Vinyals2, Oreste Gualillo3, Alfonso Corrales1, Santos Castañeda4, Raquel Lopez Mejias5, José M. Cifrián1 and Miguel Ángel González-Gay6, 1Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Department of Immunology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain, 4Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 5IDIVAL, Santander, Spain, 6Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Interstitial lung disease (ILD) may occur in patients with a rheumatic autoimmune disease (AD), increasing their morbidity and mortality [1]. In this regard, the…
  • Abstract Number: 0522 • ACR Convergence 2022

    Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis from EUSTAR

    Anna-Maria Hoffmann-Vold1, Cathrine Brunborg1, Paolo Airò2, Lidia P. Ananyeva3, László Czirják4, Serena Guiducci5, Eric Hachulla6, MENGTAO LI7, Carina Mihai8, Gabriela Riemekasten9, Petros P. Sfikakis10, Gabriele Valentini11, Otylia Kowal-Bielecka12, Yannick Allanore13 and Oliver Distler8, 1Oslo University Hospital, Oslo, Norway, 2Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy, 3V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 4Medical school of Pécs, Pecs, Hungary, 5University of Firenze, Firenze, Italy, 6University of Lille, Lille, France, 7Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China, 8Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 9University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany, 10Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, 11Università della Campania “Luigi Vanvitelli”, Napoli, Italy, 12Medical University of Bialystok, Bialystok, Poland, 13Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France

    Background/Purpose: Enrichment strategies from clinical trials for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD) have been partly successful but have not been tested in a…
  • Abstract Number: 1122 • ACR Convergence 2022

    Short Peripheral Blood Leukocyte Telomere Length in Rheumatoid Arthritis – Interstitial Lung Disease

    Pierre-Antoine Juge1, Tracy Doyle2, Seoyeon Lee3, Avram Walts4, Anthony Esposito5, Sergio Poli de Frias6, Ritu R. Gill7, Hiroto Hatabu8, Mizuki Nishino8, Michael Weinblatt9, Nancy A. Shadick6, Kristen Demoruelle10, Ivan O. Rosas11, Benjamin granger12, Kevin D Deane13, Bruno Crestani14, Paul Wolters15, Philippe Dieude16 and Joyce Lee13, 1Rheumatology department, Bichat Hospital, Paris, France, 2Brigham and Women's Hospital, Boston, MA, 3Department of Medicine, University of California, San Francisco, CA, 4Department of medicine, National Jewish Hospital, Denver, CO, 5Brigham and Women's Hospital, Department of Medicine, Boston, MA, 6Department of Medicine, Brigham and Women's Hospital, Boston, MA, 7Beth Israel Deaconess Medical Center, Radiology Department, Boston, MA, 8Department of Radiology, Brigham and Women's Hospital, Boston, MA, 9Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 10Department of Medicine, University of Colorado, Denver, CO, 11Baylor College of Medicine, Houston, TX, 12Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, PEPITES, F75013, Paris, France, Paris, France, 13University of Colorado Denver Anschutz Medical Campus, Denver, CO, 14Hopital Bichat, Paris University, Paris, France, 15UCSF, SF, 16Université Paris Cité, Paris, France

    Background/Purpose: Shortened telomere lengths (TL) have been associated with interstitial lung disease (ILD), in particular idiopathic pulmonary fibrosis (IPF). Given the phenotypic overlap between IPF…
  • Abstract Number: 1528 • ACR Convergence 2022

    Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) and Organ Damage: Data from the SENSCIS Trial

    Janet Pope1, Susanna Proudman2, Wendy Stevens3, Joerg Henes4, Rozeta Simonovska5, Margarida Alves6 and Yannick Allanore7, 1University of Western Ontario, London, ON, Canada, 2Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia, 3Department of Rheumatology, St Vincent’s Hospital, Melbourne, Australia, Melbourne, Australia, 4Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, 5mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, 6Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 7Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France

    Background/Purpose: The Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI) was developed to quantify organ damage in patients with SSc. We assessed outcomes in the SENSCIS…
  • Abstract Number: 2049 • ACR Convergence 2022

    ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive

    Anna-Maria Hoffmann-Vold1, Håvard Fretheim1, Phoung Phoung Diep1, Karoline Lerang2, Birgir Gudbransson1, Helena Andersson1, Øyvind Midtvedt1, Torhild Garen1, Michael Durheim1, Trond Mogens Aaløkken1, Øyvind Palm1 and Øyvind Molberg2, 1Oslo University Hospital, Oslo, Norway, 2Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway

    Background/Purpose: Interstitial lung disease (ILD) in primary Sjögren's syndrome (pSS) has been reported to be present in 10-15% of patients, but ILD progression in pSS-ILD…
  • Abstract Number: 0132 • ACR Convergence 2022

    Pleuroparenchymal Fibroelastosis: A Special Clinical Situation in Patients with Interstitial Lung Disease Associated with Connective Tissue Diseases. Descriptive Study from a Referral Centre

    Belén Atienza-Mateo1, Sara Remuzgo-Martinez1, Diego Ferrer2, Gerardo Blanco Rodríguez3, Sheila Izquierdo Cuervo2, Víctor M. Mora-Cuesta1, David Iturbe-Fernández1, Ricardo Blanco4, José M. Cifrián1 and Miguel Ángel González-Gay5, 1Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Department of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Department of Radiology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 5Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Pleuroparenchymal fibroelastosis (PPFE) is a rare interstitial lung disease (ILD) that can be idiopathic or associated with a variety of different conditions, including connective…
  • Abstract Number: 0585 • ACR Convergence 2022

    Baricitinib Inhibits Proinflammatoly Cytokine Production, Proliferation and Cell Migration in Human Lung Fibroblasts

    Takeo Isozaki1, Rei Takahashi2, Kohei Maeda2, Toshihiro Tanioka2, Kunika Shimizu3, Kazutaka Kawamori3, Noriko Konishi4, Shinichiro Nishimi3, Sho Ishii3, Kuninobu Wakabayashi3 and Tsuyoshi Kasama3, 1Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, 2Division of Pathogenesis and Translational Medicine, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan, 3Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Japan, 4Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction. Baricitinib is a selective small molecule inhibitor of JAK 1…
  • Abstract Number: 1123 • ACR Convergence 2022

    Excess of Rare Deleterious Variants Within JAK-STAT Pathway – Related Genes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease

    Pierre-Antoine Juge1, Steven Gazal2, Raphaël Borie3, Lidwine Wemeau4, Marie-Pierre Debray5, Sebastien Ottaviani6, Sylvain Marchand Adam7, Christophe Richez8, Hilario Nunes9, Pascal Richette10, Caroline Kannengiesser11, Jérome Avouac12, Jean Sibilia13, René-Marc Flipo14, Vincent Cottin15, Thierry Schaeverbeke16, Martin Soubrier17, Nathalie Saidenberg-Kermanac’h18, Dominique Valeyre19, Catherine Boileau11, Bruno Crestani20 and Philippe Dieude21, 1Rheumatology department, Bichat Hospital, Paris, France, 2University of Southern California, Los Angeles, CA, 3Pulmonology department, Bichat Hospital, Paris, France, 4Pulmonology department, Lille University hospital, Lille, France, 5Radiology department, Hôpital Bichat, Paris, France, 6Hopital Bichat-Claude Bernard, Paris, France, 7Pulmonology department, Tours University Hospital, Tours, France, 8Université de Bordeaux, Bordeaux, France, 9Pulmonology department, Hopital Avicenne, Bobigny, France, 10Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, 11Genetic Department, Bichat hospital, Paris, France, 12Rheumatology Department, Cochin hospital, Paris, France, 13University Hospital of Strasbourg, Strasbourg, France, 14Hôpital Roger Salengro, Lille, France, 15Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, 16FHU ACRONIM, University Hospital of Bordeaux, University of Bordeaux, Bordeaux, France, 17Gabriel-Montpied Hospital, Clermont-Ferrand, France, 18Rheumatology Department, Avicenne Hospital, Bobigny, France, 19Pulmonology department, Avicenne Hospital, Bobigny, France, 20Hopital Bichat, Paris University, Paris, France, 21Université Paris Cité, Paris, France

    Background/Purpose: Interstitial lung disease (ILD) is a leading cause of morbidity and mortality in patients with RA. To date, there are no specific treatments available…
  • Abstract Number: 1531 • ACR Convergence 2022

    Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Three-Year Data from SENSCIS-ON

    Yannick Allanore1, Madelon Vonk2, Oliver Distler3, Arata Azuma4, Maureen Mayes5, Alexandra James6, Veronika Kohlbrenner7, Margarida Alves8, Dinesh Khanna9 and Kristin Highland10, 1Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, 2Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 3Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 4Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, 5Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, 6Elderbrook solutions GmbH, Bietigheim-Bissingen, Germany, Bietigheim-Bissingen, Germany, 7Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, 8Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 9Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, 10Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH

    Background/Purpose: In the randomized placebo-controlled SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52…
  • Abstract Number: 2164 • ACR Convergence 2022

    Profibrotic Alveolar Macrophages as a Potential Biomarker in Systemic Sclerosis-associated Interstitial Lung Disease

    Nikolay Markov1, Karolina Senkow1, Anthony Esposito2, Jonathan Puchalski3, Mridu Gulati3, Erica Herzog3, Danielle Antin-Ozerkis4, Mary Carns5, Alyssa Williams6, Nic Page6, Alexander Misharin1 and Monique Hinchcliff7, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2Brigham and Women's Hospital, Department of Medicine, Boston, MA, 3Yale School of Medicine, New Haven, CT, 4Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, 5Northwestern University Division of Rheumatology, Chicago, IL, 6Yale University, New Haven, CT, 7Yale School of Medicine, Westport, CT

    Background/Purpose: Interstitial lung disease (ILD) is a leading cause of death in patients with systemic sclerosis (SSc). Previously, profibrotic monocyte-derived alveolar macrophages (MoAM) expressing (SPP1,…
  • Abstract Number: 0134 • ACR Convergence 2022

    Combination Treatment with Baricitinib and Pulse Steroids in Severe COVID19: A

    Francesco Ferro1, Elena Elefante2, Italiano Nazzareno2, Gaetano La Rocca3, Davide Schilirò2, Michele Moretti2, Roberto Mozzo4, De Simone Luigi4, Chiara Baldini5 and Marta Mosca2, 1Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, 2University of Pisa, Pisa, Italy, 3University of Pisa, Rheumatology Unit, Palermo, Palermo, Italy, 4Anesthesiology & Intensive Care Unit/Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, 5University of Pisa, Pisa, Pisa, Italy

    Background/Purpose: Growing evidence from RCTs and real-life experiences has highlighted important similarities between severe COVID19 and rapidly progressive interstitial lung diseases (RP-ILD) occurring in connective…
  • Abstract Number: 0587 • ACR Convergence 2022

    Increase of Intercellular Adhesion Molecule-1 Linked to Lung Damage of Interstitial Lung Disease in Patients with Autoimmune Diseases

    Veronica Pulito-Cueto1, Sara Remuzgo-Martinez1, Fernanda Genre1, Belén Atienza-Mateo1, David Iturbe-Fernández1, Víctor M. Mora-Cuesta1, Leticia Lera-Gómez1, Diana Prieto-Peña1, Virgi Portilla1, Ricardo Blanco2, Oreste Gualillo3, Alfonso Corrales1, José M. Cifrián1, Raquel Lopez Mejias4 and Miguel Ángel González-Gay5, 1Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain, 4IDIVAL, Santander, Spain, 5Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Intercellular adhesion molecule-1 (ICAM-1) regulates leukocyte recruitment from circulation to sites of inflammation, being considered as a marker of underlying endothelial damage [1]. Moreover,…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 39
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology